Literature DB >> 27017956

An estimating equation approach to dimension reduction for longitudinal data.

Kelin Xu1, Wensheng Guo2, Momiao Xiong3, Liping Zhu4, Li Jin5.   

Abstract

Sufficient dimension reduction has been extensively explored in the context of independent and identically distributed data. In this article we generalize sufficient dimension reduction to longitudinal data and propose an estimating equation approach to estimating the central mean subspace. The proposed method accounts for the covariance structure within each subject and improves estimation efficiency when the covariance structure is correctly specified. Even if the covariance structure is misspecified, our estimator remains consistent. In addition, our method relaxes distributional assumptions on the covariates and is doubly robust. To determine the structural dimension of the central mean subspace, we propose a Bayesian-type information criterion. We show that the estimated structural dimension is consistent and that the estimated basis directions are root-[Formula: see text] consistent, asymptotically normal and locally efficient. Simulations and an analysis of the Framingham Heart Study data confirm the effectiveness of our approach.

Entities:  

Keywords:  Central mean subspace; Dimension reduction; Estimating equation; Longitudinal data; Semiparametric efficiency; Sliced inverse regression

Year:  2016        PMID: 27017956      PMCID: PMC4803001          DOI: 10.1093/biomet/asv066

Source DB:  PubMed          Journal:  Biometrika        ISSN: 0006-3444            Impact factor:   2.445


  10 in total

1.  Dynamic conditionally linear mixed models for longitudinal data.

Authors:  M Pourahmadi; M J Daniels
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Comment: Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data.

Authors:  Anastasios A Tsiatis; Marie Davidian
Journal:  Stat Sci       Date:  2007       Impact factor: 2.901

3.  A bias correction for covariance estimators to improve inference with generalized estimating equations that use an unstructured correlation matrix.

Authors:  Philip M Westgate
Journal:  Stat Med       Date:  2012-12-16       Impact factor: 2.373

4.  Body mass index and the prevalence of hypertension and dyslipidemia.

Authors:  C D Brown; M Higgins; K A Donato; F C Rohde; R Garrison; E Obarzanek; N D Ernst; M Horan
Journal:  Obes Res       Date:  2000-12

5.  A Review on Dimension Reduction.

Authors:  Yanyuan Ma; Liping Zhu
Journal:  Int Stat Rev       Date:  2013-04       Impact factor: 2.217

6.  A Semiparametric Approach to Dimension Reduction.

Authors:  Yanyuan Ma; Liping Zhu
Journal:  J Am Stat Assoc       Date:  2012       Impact factor: 5.033

7.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study.

Authors:  Ramachandran S Vasan; Alexa Beiser; Sudha Seshadri; Martin G Larson; William B Kannel; Ralph B D'Agostino; Daniel Levy
Journal:  JAMA       Date:  2002-02-27       Impact factor: 56.272

8.  Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries.

Authors:  J V Selby; G D Friedman; C P Quesenberry
Journal:  Am J Epidemiol       Date:  1990-06       Impact factor: 4.897

Review 9.  Obesity and hypertension: epidemiological and clinical issues.

Authors:  S MacMahon; J Cutler; E Brittain; M Higgins
Journal:  Eur Heart J       Date:  1987-05       Impact factor: 29.983

10.  Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes.

Authors:  Martin G Larson; Larry D Atwood; Emelia J Benjamin; L Adrienne Cupples; Ralph B D'Agostino; Caroline S Fox; Diddahally R Govindaraju; Chao-Yu Guo; Nancy L Heard-Costa; Shih-Jen Hwang; Joanne M Murabito; Christopher Newton-Cheh; Christopher J O'Donnell; Sudha Seshadri; Ramachandran S Vasan; Thomas J Wang; Philip A Wolf; Daniel Levy
Journal:  BMC Med Genet       Date:  2007-09-19       Impact factor: 2.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.